What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 2 minute read Pharma Industry News Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective… byPallavi MadhirajuNovember 5, 2023